Pfizer Inc. which can be found using ticker (PFE) have now 20 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $42.00 and $25.00 calculating the mean target share price we have $31.09. (at the time of writing). Given that the stocks previous close was at $26.25 this would imply there is now a potential upside of 18.4%. The day 50 moving average is $26.33 and the 200 moving average now moves to $27.81. The market capitalization for the company is 145.93B. The price for the stock stands currently at: $25.75 USD
The potential market cap would be $172,855,338,829 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 18.26, revenue per share of $11.23 and a 4.64% return on assets.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
